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The ability of G protein coupled receptors to heterooligomerize and create novel 
signaling complexes has demonstrated the tremendous potential of these receptors to 
access diverse signaling cascades, as well as to modulate the nature of the transduced 
signal. In the dopamine receptor field, the existence of a D1-like receptor in brain that 
activated phospatidylinositol turnover has been shown, but definition of the molecular 
entity remained elusive. We discovered that the D1 and D2 receptors form a 
heterooligomer, which on activation of both receptors, coupled to Gq to activate 
phospholipase C and generate intracellular calcium release. The activation of Gq by the 
D1-D2 heterooligomer has been shown to occur in cells expressing both receptors, as 
well as in striatum, distinct from Gs/olf or Gi/o activation by the D1 and D2 receptor 
homooligomers, respectively. The activation of the D1-D2 receptor heterooligomer in 
brain led to a calcium signal–mediated increase in phosphorylation of calmodulin kinase 
llα. The calcium signal rapidly desensitized and the receptors cointernalized after 
occupancy of either the D1 or D2 binding pocket. Thus, the D1-D2 heterooligomer 
directly links the action of dopamine to rapid calcium signaling and likely has important 
effects on dopamine-mediated synaptic plasticity and its functional correlates in brain.  
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INTRODUCTION 
The analysis of the range of mechanisms of protein-protein interactions has revolutionized the field of G 
protein coupled receptor (GPCR) biology, and the discovery of direct receptor-receptor interactions has 
led to the investigation of the varied roles of this process in GPCR function[1,2]. The great strides 
forward that have occurred in the analysis of the tertiary and quaternary structures of GPCRs through 
biophysical, protein crystallography, and atomic force microscopy methods[3,4,5,6,7,8] have aided the 
understanding and interpretation of functional studies that revealed the presence of receptor oligomers. 
The realization of the significance of GPCR homo- and heterooligomerization[9] as these processes are George and O’Dowd: D1-D2 receptor heterooligomers  TheScientificWorldJOURNAL (2007) 7(S2), 58–63
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being further analyzed has added another degree of complexity to the understanding of this important 
class of receptors.  
One of the most exciting aspects of GPCR oligomerization has been the observation that 
heterooligomerization gives rise to receptor complexes with properties that are completely distinct from 
that of their constituent receptors. This has been shown to include novel pharmacology[10,11], masking 
the effect of one component[12,13] or enhancing the efficacy of one of the receptors[14,15], to name a 
few. Some of the functional effects mediated by GPCR heterooligomers were discovered on the basis of 
physiological findings for which activation of the known GPCRs did not provide a mechanism.  
THE SEARCH FOR A Gq-COUPLED D1 RECEPTOR 
In the dopamine receptor field, it was the quest for the Gq-coupled D1-like receptor that led us to identify 
the D1-D2 receptor heterooligomer. Although the cloning efforts of our Toronto group and others 
identified five separate dopamine receptors, which were categorized as D1-like or D2-like based on their 
pharmacological properties, gene and protein structure, G protein linkage, and ability to activate or 
attenuate adenylyl cyclase activity, these receptors provided no readily available identification of a D1-
like receptor coupled to Gq in striatum. The cloned D1 receptor, when expressed in heterologous cells, 
such as Cos7[16], HEK[17], CHO, or BHK[18] cells, did not activate a phospholipase C–dependent 
calcium signal, whereas in brain tissue[19,20] or Xenopus oocytes injected with striatal mRNA[21], there 
was evidence for a D1 receptor activated phospholipase C–mediated increase in phosphatidylinositol 
turnover. Clearly, this discrepancy suggested the presence of some endogenous mechanism in native 
tissues that was absent in all of the heterologous expression systems. A definitive pharmacological profile 
for this “D1 receptor” was not established and many studies used relatively high concentrations of drugs, 
calling into question the agonist specificity of the observed effects. This led us to consider the possibility 
that the D1 agonist stimulated phospholipase C and phosphatidylinositol turnover may have resulted from 
the coincident activation of another GPCR in brain. 
Lending further support to this notion was the long-accumulated evidence from a variety of sources 
indicating that certain dopamine D1 and D2 receptor mediated effects and behaviors were synergistic and 
resulted from the activation of both receptors. Since the molecular bases of D1 and D2 receptor 
modulation of adenylyl cyclase activity were inherently opposite, alternate mechanisms likely mediated 
these effects. The identity of the dopamine receptors that could activate inositol triphosphate production 
appeared to be distinct, because the ability of certain drugs to activate this pathway did not correlate with 
their ability to activate adenylyl cyclase[22], indicating that the Gq-coupled dopamine D1 receptor was 
distinct from the Gs/olf-coupled D1 or Gi/o-coupled D2 dopamine receptors. Since we postulated that the 
factor absent in D1-expressing heterologous cells, but present in striatal tissue, might be another GPCR, 
we considered receptors present in striatum that could be activated by high concentrations of D1 receptor 
agonists, such as the D2 dopamine receptor, since the density of D5 receptors in striatum is low. Since 
GPCRs have been shown to heterooligomerize[1], we investigated this possibility and demonstrated that 
D1 and D2 receptors were present within a certain proportion of striatal neurons using selective 
antibodies that were specific without cross-reactivity to any of the other dopamine receptors[17]. The 
ability to coimmunoprecipitate the D1 receptor along with the D2 receptor and vice versa from cells 
coexpressing both receptors, as well as from striatal tissue, indicated that the receptors were expressed 
within the same signaling complex in cells and in brain. Furthermore, biophysical analytic methods to 
evaluate energy transfer using cell surface FRET[23] or BRET throughout the cell (unpublished) reveal 
that the D1 and D2 receptors exist together in close proximity of 50–100 Å on the cell surface and within 
the endoplasmic reticulum.  George and O’Dowd: D1-D2 receptor heterooligomers  TheScientificWorldJOURNAL (2007) 7(S2), 58–63
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DOPAMINE ACTIVATES A CALCIUM SIGNAL THROUGH THE D1-D2 
HETEROOLIGOMER 
Since the classical signaling pathways activated by D1 and D2 dopamine receptors involve the 
stimulation or attenuation of adenylyl cyclase–mediated generation of cyclic AMP, it appeared unlikely 
that the D1-D2 heterooligomer would function through a cyclic AMP–related mechanism. Therefore, we 
investigated other second messenger pathways and demonstrated that activation of both receptors within 
the D1-D2 heterooligomer triggered intracellular calcium release through a Gq-mediated phospholipase 
C–dependent pathway[17]. The calcium signal was attenuated by an antagonist of either the D1 or D2 
receptor, indicating the necessity for activation of both constituents of the heterooligomer to elicit the 
signal. Further characterization of the D1-D2–activated calcium signal has delineated the cascade to 
include activation of the inositol triphosphate receptor and lack of a role for extracellular calcium 
influx[24]. Roles for other intracellular pathways that could trigger calcium release have been excluded 
through the use of inhibitors of multiple components of these signaling cascades.  
ACTIVATION OF THE D1-D2 HETEROOLIGOMER IN STRIATUM 
The activation of the D1-D2 heterooligomer by dopamine agonists in rat and mouse striatum induced 
rapid activation of Gq/11, as indicated by direct GTPγ
35S incorporation into the G protein[24]. This was 
absent in both D1 or D2 receptor gene-deleted animals, underscoring the need for involvement of both 
receptors for the Gq activation effect. Furthermore, just as documented in the heterologous cell lines, 
treatment with either the D1 or D2 receptor antagonist abolished the effect of agonist activation, 
emphasizing the necessary participation of both of the constituent receptors in generating the functional 
response. Thus, the presence and activation of both D1 and D2 receptors within the heterooligomeric 
complex appears necessary for activation of Gq in striatum by dopamine agonists.  
Generation of a dopamine-triggered calcium signal through D1-D2 heteromer activation will lead to 
the initiation of several signaling cascades subsequently. One of the more immediate consequences of this 
would be activation of calmodulin and calmodulin kinase (CaMK). Since CaMKllα is the most abundant 
isoform of CaMK relevant for synaptic functions, we examined the effect of the calcium signal activation 
on CaMKllα function. Within 5–10 min following concurrent administration of a D1 and D2 agonist 
given intraperitoneally to mice and rats, we found marked increases of phosphorylated CaMKllα in 
neurons of nucleus accumbens shell and certain areas of caudate nucleus. This increase could be blocked 
by preadministration of the D1 antagonist SCH 23390 or the D2 antagonist raclopride, and did not occur 
in D1 or D2 gene-deleted mice[24]. Blocking NMDA receptors using MK-801 had only a minor effect on 
the phospho-CaMKllα levels generated following D1-D2 heteromer activation.  
DEFINING A NOVEL PHARMACOLOGY FOR THE D1-D2 HETEROOLIGOMER  
Our early studies examining dopamine or the commonly used D1 or D2 dopamine agonists (e.g., SKF 
81297 or quinpirole) found no differences between the ligand binding pocket of the D1 or D2 receptor 
within the D1-D2 heterooligomer with that within their respective homooligomers[23]. The D1 and D2 
receptor selective antagonists also had unaltered binding characteristics whether binding to the receptors 
within the homooligomer or heterooligomer. However, since the G protein specificity of the D1-D2 
heterooligomer differed from that of the D1 and D2 homooligomers, we reasoned that there could be 
significant alterations to the intracellular domains of the receptors that enabled coupling to a different G 
protein and thus postulated that there may also be alterations to the ligand binding pockets. We therefore 
screened a number of diverse dopaminergic agonists to detect these differences. Using a series of SKF 
compounds, we identified several interesting pharmacological profiles with differential specificity for the George and O’Dowd: D1-D2 receptor heterooligomers  TheScientificWorldJOURNAL (2007) 7(S2), 58–63
 
  61
receptor homo- and heterooligomers. For instance, the commonly used D1 agonist SKF 81297 had potent 
affinity for the D1 receptor in D1-D2 and D1-D1 complexes, with KD values in the nanomolar range. This 
agonist robustly stimulated Gs-mediated adenylyl cyclase activity as well as Gq-mediated intracellular 
calcium release. In contrast, two other SKF compounds of interest include SKF 83959 and SKF 83822, 
both of which had indistinguishable high binding affinity for the D1 receptor in D1-D2 or D1-D1 
complexes. However, we showed that these agonists had very specific functional effects, since SKF 
83959 robustly stimulated a calcium signal and did not activate adenylyl cyclase, whereas SKF 83822 
robustly stimulated adenylyl cyclase with no effect to stimulate calcium release. Thus, these agonists had 
selective actions to activate the D1-D2 heterooligomer and the D1-D1 homooligomer, respectively[24].  
Since many of our other studies in vitro and in vivo had indicated the necessity of occupying and 
activating both D1 and D2 receptors, it appeared paradoxical that certain SKF “D1 agonists” could 
generate a calcium signal by their sole administration. We investigated this by examining the binding 
pockets within each receptor and determined that these D1 agonists could activate Gq/11 by acting as a 
full agonist at the D1 receptor and a partial agonist at the D2 receptor within the D1-D2 heteromeric 
complex[24]. This was verified experimentally by two strategies. First, comparison of the peak heights of 
the calcium signal generated by the SKF compounds revealed it was 60–75% of that generated by 
dopamine, and second, coadministration of the D2 agonist quinpirole with the SKF agonists increased 
calcium release maximally, to the same extent as with dopamine[24,25]. Furthermore, the use of pertussis 
toxin (PTX) to uncouple Gi/o proteins from D2 and render the D2 homooligomer of low affinity to 
agonists revealed that SKF 81297 and SKF 83959 bound to a PTX-insensitive D2 receptor with high 
affinity, which represents the D2 receptor linked to the PTX-insensitive Gq protein. These agonists 
detected a high-affinity PTX-resistant D2 site that was documented in rat and mouse striatum, as well as 
in cells expressing D1-D2 complexes, but was absent in cells expressing only D1 or D2 receptors or in D1 
gene-deleted animals. These results indicate that the presently accepted pharmacological profile for 
dopamine agonists will need to be re-examined and revised to include the rank orders at each of the 
distinct D1-D2, D1-D1, and D2-D2 receptor signaling complexes. 
TURNING OFF THE CALCIUM SIGNAL 
The peak height of the calcium signal activated by the D1-D2 heterooligomer occurs within a few seconds 
of agonist administration and was found to desensitize within minutes[25]. Interestingly, agonist 
occupancy of either ligand binding pocket within the heterooligomer resulted in desensitization of the 
calcium signal. Pretreatment with either a D1 or a D2 agonist induced desensitization. Exclusive 
occupancy of the D1 binding pocket was ensured by coadministration of a D2 antagonist. Following this 
pretreatment, the dopamine-stimulated calcium signal was blunted and desensitized. Similarly, 
pretreatment with a D2 agonist with the D1 binding pocket occluded by an antagonist also resulted in 
desensitization to subsequent dopamine activation. However, the kinetics of desensitization was different 
based on whether the D1 or D2 receptor was occupied by agonist. Desensitization by D1 receptor 
occupancy was most rapid, occurring with a half-life of 2 min, whereas desensitization by D2 receptor 
occupancy occurred with a half-life of 10 min[25]. The mechanism of desensitization involved the 
noncatalytic actions of GPCR kinases 2 and 3. The heteromeric complexes underwent internalization 
documented 20 min after agonist activation. The removal of the complexes off the cell surface occurred 
following occupancy of either the D1 or D2 binding pocket[25]. 
SUMMARY AND SIGNIFICANCE 
We have identified a novel mechanism through which dopamine can activate the fast-signaling 
intracellular calcium release machinery in brain through the activation of D1-D2 heterooligomers. 
Calcium signaling has important roles in many aspects of neuronal function, and activation of the calcium George and O’Dowd: D1-D2 receptor heterooligomers  TheScientificWorldJOURNAL (2007) 7(S2), 58–63
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signaling cascade will enable dopamine neurotransmission to have rapid and direct effects on synaptic 
plasticity and long-term changes as a consequence. The delineation of the functional responses mediated 
by the activation of the D1-D2 dopamine receptor heterooligomer will dissect out its potential roles in 
cognition, learning, and memory, as well as in the pathological processes related to disorders such as 
schizophrenia and drug addiction.  
Stemming from our realization that oligomerization is an important characteristic of the structure and 
function of GPCRs, heterooligomerization presents yet another novel facet of these receptors, increasing 
the complexity of the mechanisms of action of neurotransmitters, established drugs, and the molecular 
models of diseases that have been studied for many years. Increased understanding of the full implications 
of these receptor-receptor interactions among GPCRs will undoubtedly yield significant insights into their 
function and the behaviors and clinical disorders that are mediated by these receptors.  
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